Is There a Role for Triplet Therapy in Low-Volume mCSPC?


A brief discussion on the use of doublet versus triplet therapy in patients with low-volume metastatic prostate cancer.


Neeraj Agarwal, MD: Bobby, how do you approach this? We have this patient with high-volume disease. Let’s say the patient had low-volume disease that is still de novo. How are the processes different? How will you treat them differently from high-volume de novo disease?

Bobby Liaw, MD: I’ll quickly take a small trip back to the PEACE1 data. PEACE1 included patients with low-volume disease, and it also tried to understand what benefit the triplet regimen confers on these patients. With the most recent data analysis, there haven’t been any conclusive responses in terms of overall survival benefit for these low-volume patients. Further longitudinal follow-up may change that, but unfortunately there’s not a lot of strong evidence that patients with low-volume disease would necessarily benefit from a triplet regimen.

For low-volume patients, I’m not going to try to persuade them to take 3 different therapies at the same time. There are some exceptions to that. When we define high-volume disease, we’re looking at the CHAARTED criteria, which is primarily focused on the number of lesions. They don’t get at the heart of the matter: the overall actual volume of disease. One tiny, 0.5-mm bone lesion still counts as a bone lesion for CHAARTED. But if you have a 10-cm lymph node that’s obstructing kidney function, that’s still 1 lesion.

There are well-known, poor prognostic features of disease that CHAARTED doesn’t fully accommodate, such as Gleason score and height of PSA [prostate-specific antigen]. There are some gray areas. Even if someone has low-volume disease, with very large, obstructive lymph nodes, that doesn’t meet high-volume disease criteria. But if you need something, if they’re highly symptomatic and they need an immediate response, then there’s room to make a case for much more aggressive triplet-type therapy. Does that mean that it’s necessarily better over a doublet? I don’t have those data. I don’t know.

To your point, I don’t know if we’re going to have great randomized prospective studies to demonstrate this in the near future. Most likely, we’re going to have to come together as a medical community to understand what the real-world data tell us to help inform some of these decision-making processes. But for low-volume patients, I’m still mostly thinking about doublet therapies.

Neeraj Agarwal, MD: Thank you.

Transcript edited for clarity.

Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Related Content